Biocon's insulin biosimilar Glargine gets preference in top US formulary

The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in July this year


An insulin biosimilar called Glargine, co-developed by Biocon Biologics and US pharma company Viatris, will be listed by pharmacy benefit management organisation Express Scripts as a preferred insulin brand  on

Also Read

USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance

Adar Poonawalla-backed pharmacy chain Wellness Forever files for IPO

Apollo's digital platform move may fuel consolidation, benefit consumers

S&P upgrades Tata Steel, Tata Motors, JLR ratings over Tata Sons' influence

IDfy raises Rs 86 cr in series D funding led by TransUnion, Blume Ventures

Supreme Court rejects bail plea of ex-Amrapali director on medical grounds

Reliance Naval and Engineering lenders ask bidders to sweeten offers

Nirav Modi UK extradition appeal to be heard on December 14

First Published: Oct 21 2021 | 12:19 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to